<?xml version='1.0' encoding='utf-8'?>
<record xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
			<header>
				<identifier>oai:bovine-ojs-tamu.tdl.org:article/6617</identifier>
				<datestamp>2020-08-21T22:22:43Z</datestamp>
				<setSpec>aabp:RD</setSpec>
			</header>
			<metadata>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">AT-4526, A New Quinolone Derivative:  Its In Vitro and In Vivo Antibacterial Activity as a Veterinary Medicine</dc:title>
	<dc:creator xml:lang="en">Sakaguchi, Yuzo</dc:creator>
	<dc:creator xml:lang="en">Kouno, Kaoru</dc:creator>
	<dc:creator xml:lang="en">Nakai, Masahiro</dc:creator>
	<dc:creator xml:lang="en">Matsumoto, Shuji</dc:creator>
	<dc:creator xml:lang="en">Katae, Hiromi</dc:creator>
	<dc:creator xml:lang="en">Hattori, Hiroaki</dc:creator>
	<dc:creator xml:lang="en">Nakamura, Shinichi</dc:creator>
	<dc:subject xml:lang="en">AT-4526</dc:subject>
	<dc:subject xml:lang="en">field isolates</dc:subject>
	<dc:subject xml:lang="en">antibacterial activities</dc:subject>
	<dc:subject xml:lang="en">in vitro</dc:subject>
	<dc:subject xml:lang="en">in vivo</dc:subject>
	<dc:subject xml:lang="en">bacterial infections</dc:subject>
	<dc:subject xml:lang="en">antibiotic resistance</dc:subject>
	<dc:description xml:lang="en">Various antibiotics have been used in the treatment of bacterial infections in domestic animals. In recent years, however, outbreaks of infections due to microorganisms resistant to antibiotics are often observed (1, 2, 3). The antibacterial quinolone derivatives does not show cross-resistance with antibiotics (4). AT-4526, 1-cyclopropyl-5,6,8-trifluoro-1 ,4- dihydro-7-(cis-3,5-dimethyl-1-piperazinyl)-4-oxoquinoline-3- carboxylic acid (Fig. 1), is a new quinolone derivative which was synthesized in 1986 (5). This compound, as well as the structurally related enrofloxacin (6), has a high order of activity against a broad spectrum of gram-positive, gram-negative bacteria, and Mycoplasma spp ..
This paper describes the in vitro and in vivo antibacterial activities of AT-4526 against field isolates in domestic animals and the comparison with those of enrofloxacin (ERFX), oxytetracycline (OTC), tylosin (TS), thiamphenicol (TP), kanamycin (KM) and ampicillin (ABPC).</dc:description>
	<dc:publisher xml:lang="en">American Association of Bovine Practitioners</dc:publisher>
	<dc:date>1992-08-31</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://bovine-ojs-tamu.tdl.org/aabp/article/view/6617</dc:identifier>
	<dc:identifier>10.21423/aabppro19926617</dc:identifier>
	<dc:source xml:lang="en">American Association of Bovine Practitioners  Conference Proceedings; 1992: Volume 3; 192-198</dc:source>
	<dc:source>1079-9737</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://bovine-ojs-tamu.tdl.org/aabp/article/view/6617/7178</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 1992 American Association of Bovine Practitioners</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		
